Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Capricor secures reprieve as FDA extends DMD cell therapy review
The FDA deferred its decision to review information the biotech submitted after a negative advisory committee vote.
Nick Paul Taylor
Aug 25, 2026 3:26am
Capricor soars on plan to amend DMD filing after adcomm setback
Aug 14, 2026 10:20am
FDA adcomm shoots down Capricor's Duchenne cell therapy
Jul 29, 2026 6:06pm
Satellos’ ‘intriguing’ DMD data raise hopes ahead of key readout
Jul 8, 2026 9:48am
Big Pharma-backed SonoThera sounds off with $125M series B
Jun 10, 2026 10:48am
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit
Jun 1, 2026 8:31am
